Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
296 stopped studies mapped to Breast Adenocarcinoma and descendants · 97% state a reason
Over the 296 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2…(ELPIS) | Phase 2 | terminated | Oct 8, 2020 | Fundacio Clinic Barcelona | The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize… | Enrollment / accrual |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2… | Phase 1 | terminated | Sep 23, 2022 | Baptist Health South Florida | Slow enrollment | Enrollment / accrual |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | Phase 2 | terminated | Aug 3, 2021 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast… | Phase 2 | terminated | Jul 21, 2017 | University of Chicago | side effects (rash) | Other (stated, no rule matched) |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in…(TrasTUCAN) | Phase 2 | terminated | Oct 17, 2022 | Spanish Breast Cancer Research Group | The study was closed early due to safety concerns and an unfavorable benefit-risk balance.… | Safety / toxicity |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Phase 2 | terminated | Jul 20, 2023 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced… | Phase 1 | terminated | Oct 18, 2016 | Novartis Pharmaceuticals | The early termination was based on a business decision that FAZ053 would no longer be formulated… | Safety / toxicity |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | Phase 1 | suspended | Sep 17, 2025 | Rutgers, The State University of New Jersey | 10th patient enrolled; interim analysis to be completed by HROC after 3-month follow-up completed… | Efficacy / futility |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally…(ELEVATE TNBC) | Phase 2 | terminated | Jul 12, 2021 | Gilead Sciences | Sponsor decision to terminate study. | Sponsor / business decision |
| NCT04419181 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | Phase 2 | withdrawn | Jun 5, 2020 | University of Rochester | Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials… | Other (stated, no rule matched) |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | Phase 2 | terminated | Apr 3, 2019 | Zenith Epigenetics | Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued… | Safety / toxicity |
| NCT04108858 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance… | Phase 1 / Phase 2 | terminated | Sep 30, 2019 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03535506 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for…(WI223281) | Phase 2 | terminated | May 24, 2018 | Georgetown University | lack of accrual | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based… | Phase 2 | terminated | Jan 31, 2020 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab… | Phase 1 / Phase 2 | terminated | Feb 20, 2020 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for… | Phase 2 | terminated | Sep 10, 2025 | National Cancer Centre, Singapore | Difficulty in enrolling patients with the illness under study. | Enrollment / accrual |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | CytoDyn, Inc. | Study terminated prematurely due to business reasons. Participants are no longer examined or… | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast…(PEAR-TNBC) | — | terminated | Jun 28, 2022 | Ourotech, Inc. | Lack of funding | Funding |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or…(Panthera) | Phase 1 | terminated | Aug 1, 2019 | Cancer Trials Ireland | Accrual rate to date was too low to finish the trial in a reasonable timeframe | Enrollment / accrual |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | Phase 2 | terminated | Mar 29, 2022 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed. | Enrollment / accrual |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | Early Phase 1 | withdrawn | Feb 7, 2024 | Virginia G. Kaklamani | Unable to enroll to study. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT01722890 | CharactHer. ICORG 12-09, V3 | — | terminated | Nov 7, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT05511844 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | Phase 1 | terminated | Aug 23, 2022 | Orum Therapeutics USA, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05447910 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative… | — | terminated | Jul 7, 2022 | Mayo Clinic | insufficient funding | Funding |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2021 | M.D. Anderson Cancer Center | Termination was requested by study supporter IKENA oncology | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting…(neoBREASTIM) | Phase 1 / Phase 2 | terminated | Oct 4, 2023 | Institut Curie | insufficient recruitment | Enrollment / accrual |
| NCT04789096 | Tucatinib Together With Pembrolizumab and Trastuzumab(TUGETHER) | Phase 2 | terminated | Mar 9, 2021 | Breast Cancer Trials, Australia and New Zealand | Stopped on the recommendation of the BCT Independent Data and Monitoring Committee | Other (stated, no rule matched) |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients…(PERSEVERE) | Phase 2 | terminated | Apr 19, 2021 | Bryan Schneider, MD | Funder Decision | Other (stated, no rule matched) |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple… | Phase 1 | terminated | Nov 15, 2018 | Novartis Pharmaceuticals | This was a sponsor decision and was not a consequence of any safety concern | Safety / toxicity |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | Phase 2 | terminated | Feb 5, 2020 | University of Utah | PI is leaving the institution. | Other (stated, no rule matched) |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2013 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by Sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials